The latest biotech news

News and Trends 12 Sep 2022

PDC*line Pharma presents results from phase I/II trial

PDC*line Pharma, a clinical stage biotech company developing a new class of potent and scalable active immunotherapies for cancers, has revealed the first results of its PDC-LUNG-101 phase I/II clinical trial with PDC*lung01. PDC*lung01 is the company’s therapeutic off-the shelf cancer vaccine candidate for non-small cell lung cancer (NSCLC). The preliminary data was presented at […]

September 12, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 12 Sep 2022

Enterome presents more data on therapeutic cancer treatment

Clinical stage biopharma company Enterome has presented new data from its two phase 1/2 clinical trials of its OncoMimics cancer immunotherapy EO2401. The trails are in combination with nivolumab (Opdivo) +/- bevacizumab (Avastin), in patients with first progression/recurrence of glioblastoma (ROSALIE trial), and in combination with nivolumab in patients with non-resectable adrenocortical carcinomas (ACC) and […]

September 12, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 12 Sep 2022

Astellas, Seagen and Merck give details on urothelial cancer treatment

Astellas Pharma Inc., Seagen Inc. and Merck (known as MSD outside of the U.S. and Canada), have announced results from the phase 1b/2 EV-103 clinical trial (KEYNOTE-869) Cohort K investigating PADCEV (enfortumab vedotin-ejfv) in combination with Merck’s anti-PD-1 therapy KEYTRUDA (pembrolizumab) and PADCEV alone as first-line treatment in patients with unresectable locally advanced or metastatic […]

September 12, 2022 - 5 minutesmins - By Jim Cornall

News and Trends 12 Sep 2022

Treatment for adults with moderate to severe psoriasis approved by FDA

A treatment for adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy has been approved by the U.S. Food and Drug Administration (FDA). Bristol Myers Squibb made the announcement today (September 12) that its allosteric tyrosine kinase 2 (TYK2) inhibitor, Sotyku (deucravacitinib) had been approved based on results from a phase […]

September 12, 2022 - 3 minutesmins - By Liza Laws

News and Trends 12 Sep 2022

Could combining biotech and photosynthetic cyanobacteria help the energy crisis?

A group of researchers in Switzerland is using photosynthetic bacteria to generate energy. After implanting nanotubes into them, the bacteria can create energy. And when the cells divide, those nanotubes stay with subsequent generations. While there’s a long way to go, and many questions to be answered, Ardemis Boghossian at EPFL’s School of Basic Sciences […]

September 12, 2022 - 6 minutesmins - By Jim Cornall

News and Trends 12 Sep 2022

Sensorion receives positive opinion from EMA for treatment of hearing loss

The European Medicines Agency (EMA) through its Committee for Orphan Medicinal Products (COMP) has adopted a positive opinion for a treatment for otoferlin gene mediated hearing loss. Clinical-stage biotech, Sensorion, announced the news today (September 12) that its application for an Orphan Drug Designation (ODD) for its lead therapy gene candidate, OTOF-GT will now be […]

September 12, 2022 - 3 minutesmins - By Liza Laws

News and Trends 12 Sep 2022

Ayala Pharmaceuticals presents interim data on desmoid tumor trial

Clinical oncology company Ayala Pharmaceuticals, Inc. has announced updated, positive interim results from part A of its ongoing RINGSIDE pivotal phase 2/3 clinical trial evaluating investigational new drug AL102 in desmoid tumors. Ayala Pharmaceutical’s AL102 is a selective, oral gamma-secretase inhibitor. The data are being featured in an oral presentation at the European Society for […]

September 12, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 12 Sep 2022

First patient enrolled in phase 3 study of drug for Charcot-Marie-Tooth disease

The first patient has been enrolled in a phase 3 study of a treatment for type 1A Charcot-Marie-Tooth Disease (CMT1A) in the U.S., it was announced today (September 12). Charcot-Marie-Tooth disease is a group of inherited conditions that damage the peripheral nerves and a treatment is being developed by French biopharmaceutical company, Pharnext. The PREMIER […]

September 12, 2022 - 3 minutesmins - By Liza Laws

News and Trends 12 Sep 2022

Reveal Genomics reveals more HER2DX breast cancer validation data

Reveal Genomics, S.L. says it has received more validation of HER2DX, the world’s first specialized genomic test for HER2+ breast cancer. Valentina Guarneri from the University of Padova presented the data at the European Society of Medical Oncology Congress 2022 in Paris, France. The data obtained from the analysis of tumor samples from the PerELISA […]

September 12, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 12 Sep 2022

SiSaf reveals positive preclinical data in siRNA program to treat osteopetrosis

SiSaf Ltd, an RNA delivery and therapeutics company, has announced positive data confirming safety and efficacy of its Bio-Courier next generation silicon stabilized hybrid lipid nanoparticles (sshLNP) as an effective non-viral delivery system for autosomal dominant osteopetrosis type 2 (ADO2) siRNA therapy. The data was presented at the American Society of Bone and Mineral Research […]

September 12, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 12 Sep 2022

Cuffless device worn 24/7 can lower blood pressure, says Aktiia

A company making cuffless monitors for blood pressure says a significant and sustained reduction has been achieved for patients wearing the monitor 24/7. The device, made by Aktiia, measures blood pressure at optimal times throughout the day and night and was used in a study on hypertensive patients using a data set of more than […]

September 12, 2022 - 2 minutesmins - By Liza Laws

News and Trends 12 Sep 2022

Shasqi moves to phase 2 solid tumor study

Shasqi, a clinical-stage biotechnology company developing oncology therapeutics with its proprietary Click Activated Protodrugs Against Cancer (CAPAC) platform says it has opened the phase 2 part of its phase 1/2a clinical study to further assess SQ3370 in anthracycline-naïve patients. The phase 2 study follows the company’s presentation at the European Society for Medical Oncology (ESMO) […]

September 12, 2022 - 3 minutesmins - By Jim Cornall

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

News and Trends

PDC*line Pharma presents results from phase I/II trial

Enterome presents more data on therapeutic cancer treatment

Astellas, Seagen and Merck give details on urothelial cancer treatment

Treatment for adults with moderate to severe psoriasis approved by FDA

Could combining biotech and photosynthetic cyanobacteria help the energy crisis?

Sensorion receives positive opinion from EMA for treatment of hearing loss

Ayala Pharmaceuticals presents interim data on desmoid tumor trial

First patient enrolled in phase 3 study of drug for Charcot-Marie-Tooth disease

Reveal Genomics reveals more HER2DX breast cancer validation data

SiSaf reveals positive preclinical data in siRNA program to treat osteopetrosis

Cuffless device worn 24/7 can lower blood pressure, says Aktiia

Shasqi moves to phase 2 solid tumor study

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!